EUVIMEDEUVIMED entdecken
Crossref

Diagnostic and Prognostic Performance of the Agile 3+ Score in Patients With Chronic Hepatitis B and Concurrent MASLD After Complete Viral Suppression With Nucleos(t)ide Analogues

Hongsheng Yu, Jianhao Wu iD, Mingkai Li, Can Hu, Yuexiang Ren, Hao Jiang, Yinan Huang, Yiming Lei, Jianning Chen iD, Bin Wu iD, Yidong Yang iD

Journal of Gastroenterology and Hepatology · 2025

DOI: 10.1111/jgh.70099 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gastroenterology and Hepatology, 2025. Verfasst von Hongsheng Yu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Antiviral Agents, Liver Cirrhosis, Nucleosides. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: Natural Science Foundation of Guangdong Province for Distinguished Young Scholar, Natural Science Foundation Team Project of Guangdong Province, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The applicability of the Agile 3+ score to patients with CHB–MASLD receiving antiviral therapy remains unexplored. Our objective was to explore the diagnostic and prognostic performances of the Agile 3+ score in patients with CHB–MASLD.

Methods

This retrospective cohort study included consecutively enrolled patients with CHB and concurrent MASLD from 2014 to 2020. In Part 1, we evaluated the performance of the Agile 3+ score in predicting advanced fibrosis. In Part 2, the Agile 3+ score was applied to a follow‐up cohort to assess its correlation with liver‐related events.

Results

Among the 2492 patients evaluated by vibration‐controlled transient elastography, 103 patients with CHB and hepatic steatosis were included in the biopsy cohort, and 716 patients were included in the follow‐up cohort. The Agile 3+ score had the highest AUROC of 0.916 for the prediction of advanced fibrosis, outperforming the FIB‐4 score (0.845), NFS (0.838), and APRI (0.726). In predicting liver‐related events (LREs), the AUROC of the Agile 3+ score was also significantly higher (0.795 at 3 years, 0.809 at 5 years, and 0.834 at 8 years) than those of the other noninvasive tests. When the recommended cutoffs (0.451 and 0.679) were applied for MASLD risk stratification, the high‐risk group (HR = 13.61) and intermediate‐risk group (HR = 3.53) had significantly greater risks of LREs than the low‐risk group.

Conclusion

In patients with CHB and concurrent MASLD receiving antiviral therapy, the Agile 3+ score effectively identifies advanced fibrosis and predicts LRE risk, supporting its clinical utility in this population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis B, ChronicAntiviral AgentsLiver CirrhosisNucleosidesHumansMaleFemaleRetrospective StudiesPrognosisMiddle AgedAdultElasticity Imaging TechniquesSustained Virologic ResponseFollow-Up StudiesPredictive Value of TestsSeverity of Illness Index

Stichwörter der Autor:innen

chronic hepatitis Bhepatic steatosisliver fibrosisnoninvasive test

Substanzen

Antiviral AgentsNucleosides

Autor:innen und Institutionen

  • Department of Gastroenterology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
  • Guangdong Provincial Key Laboratory of Liver Disease Research, Guangzhou, Guangdong, China.
  • Department of Emergency, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
  • Department of Gastroenterology, Shenzhen Hospital, Southern Medical University, Shenzhen, People's Republic of China.
  • Department of Pathology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
  • Department of Pathology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.

ORCID-Profile: Jianhao Wu, Jianning Chen, Bin Wu, Yidong Yang

Förderung

  • Natural Science Foundation of Guangdong Province for Distinguished Young Scholar
  • Natural Science Foundation Team Project of Guangdong Province
  • National Natural Science Foundation of China
  • National Key Research and Development Program of China

Zitieren

APA

Yu, H., Wu, J., Li, M., Hu, C., Ren, Y., Jiang, H., Huang, Y., Lei, Y., Chen, J., Wu, B., & Yang, Y. (2025). Diagnostic and Prognostic Performance of the Agile 3+ Score in Patients With Chronic Hepatitis B and Concurrent MASLD After Complete Viral Suppression With Nucleos(t)ide Analogues. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.70099

Vancouver

Yu H, Wu J, Li M, Hu C, Ren Y, Jiang H, et al. Diagnostic and Prognostic Performance of the Agile 3+ Score in Patients With Chronic Hepatitis B and Concurrent MASLD After Complete Viral Suppression With Nucleos(t)ide Analogues. Journal of Gastroenterology and Hepatology. 2025. doi:10.1111/jgh.70099

BibTeX
@article{Yu2025,
  author = {Yu, Hongsheng and Wu, Jianhao and Li, Mingkai and Hu, Can and Ren, Yuexiang and Jiang, Hao and Huang, Yinan and Lei, Yiming and Chen, Jianning and Wu, Bin and Yang, Yidong},
  title = {Diagnostic and Prognostic Performance of the Agile 3+ Score in Patients With Chronic Hepatitis B and Concurrent MASLD After Complete Viral Suppression With Nucleos(t)ide Analogues},
  journal = {Journal of Gastroenterology and Hepatology},
  year = {2025},
  doi = {10.1111/jgh.70099}
}
Kostenlos starten →